中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.022 seconds)

    DESIGNER PEPTIDE-BASED PCV2 VACCINE
    1.
    发明申请
    DESIGNER PEPTIDE-BASED PCV2 VACCINE 审中-公开
    基于设计者基于PCV2的疫苗

    公开(公告)号：WO2012005732A1

    公开(公告)日：2012-01-12

    申请号：PCT/US2010/041406

    申请日：2010-07-08

    Applicant: UNITED BIOMEDICAL, INC ,  WANG, Chang Yi ,  PENG, Wen-Jiun

    Inventor： WANG, Chang Yi ,  PENG, Wen-Jiun

    IPC: A61K39/12

    CPC classification number: C07K14/01 ,  A61K39/12 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/6031 ,  C12N2710/24111 ,  C12N2710/24143 ,  C12N2770/32011 ,  C12N2770/32034 ,  G01N33/6878

    Abstract: Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.

    Abstract translation: 描述了包含源自PCV2衣壳蛋白的肽抗原的猪圆环病毒（PCV2）疫苗组合物。 在各种实施方案中，肽抗原含有约氨基酸47至约氨基酸202的衣壳蛋白的氨基酸。在一些实施方案中，肽抗原任选地与人工T辅助表位连接和/或与衍生的T辅助表位混合 来自PCV2的ORF1和ORF3蛋白。 还描述了使用PCV2疫苗组合物的方法。 在各种实施方案中，疫苗组合物用于动物以预防PCV2感染。 在其它实施方案中，PCV2疫苗组合物用作诊断PCV2感染的抗原。

    METHODS FOR IDENTIFYING AND USING LOW/NON-ADDICTIVE OPIOID ANALGESICS
    2.
    发明申请
    METHODS FOR IDENTIFYING AND USING LOW/NON-ADDICTIVE OPIOID ANALGESICS 审中-公开
    识别和使用低/非阿片类药物的方法

    公开(公告)号：WO1994006426A1

    公开(公告)日：1994-03-31

    申请号：PCT/US1993008869

    申请日：1993-09-17

    Applicant: QIN, Bo-yi ,  SHEN, Ke-fei ,  GONG, Xiong-qi ,  CRAIN, Stanley, M. ,  MAO, Huang ,  WANG, Chang, Yi

    IPC: A61K31/46

    CPC classification number: G01N33/9486 ,  A61K31/00 ,  A61K31/137 ,  A61K31/485 ,  G01N33/94 ,  G01N2500/10 ,  A61K2300/00

    Abstract: The present invention relates to a method of using a bioassay consisting of an electrophysiological method and a cell culture system of dorsal-root ganglion (DRG) neurons to screen and identify opioids with a high potential for use as "low- or non-addictive" analgesics. Another aspect of the invention relates to a specific group of opioid alkaloids and analogues thereof identified by the bioassay of the invention for the unique ability to activate only inhibitory, but not excitatory, opioid receptor function, for use as low- or non-addictive analgesics. Another aspect of the invention relates to the specific use of etorphine or dihydroetorphine of the opioid alkaloid family as low- or non-addictive analgesics and for the treatment of opioid addiction. The present invention also relates to the preparation of dihydroetorphine hydrochloride (7(alpha)-(1-(R)-hydroxy-1-methylbutyl)-6,14-endo-ethano-tetrahydrooripavine hydrochloride) and a pharmaceutical composition comprising the compound as an active ingredient in the form of a pharmaceutically acceptable salt.

    Abstract translation: 本发明涉及使用由电生理学方法和背根神经节（DRG）神经元的细胞培养系统组成的生物测定法来筛选和鉴定具有高潜力用作“低或非成瘾性”的阿片样物质的方法， 镇痛药。 本发明的另一方面涉及通过本发明的生物测定鉴定的特定组的阿片样物质生物碱及其类似物，其特征在于仅使用抑制性但不兴奋性的阿片受体功能仅用于作为低或非成瘾性止痛剂 。 本发明的另一方面涉及阿片样物质生物碱家族的吗啡或二氢阿托啡作为低或非成瘾止痛剂和用于治疗阿片样物质成瘾的具体用途。 本发明还涉及二氢阿托啡盐酸盐（7（α） - （1-（R） - 羟基-1-甲基丁基）-6,14-内 - 乙酸 - 四氢奥帕匹酸盐酸盐的制备）和包含该化合物 呈药学上可接受的盐形式的活性成分。

    VACCINE COMPOSITIONS AGAINST SARS-COV-2 VARIANTS OF CONCERN TO PREVENT INFECTION AND TREAT LONG-HAUL COVID
    3.
    发明申请
    VACCINE COMPOSITIONS AGAINST SARS-COV-2 VARIANTS OF CONCERN TO PREVENT INFECTION AND TREAT LONG-HAUL COVID 审中-公开

    公开(公告)号：WO2023064708A1

    公开(公告)日：2023-04-20

    申请号：PCT/US2022/077748

    申请日：2022-10-07

    Applicant: WANG, Chang-Yi

    Inventor： PENG, Wen-Jiun

    IPC: A61K39/215 ,  A61P31/14 ,  A61P31/12

    Abstract: The present disclosure is directed to amino acid sequences from SARS-CoV-2 S1-RBD variants of concern (VoCs) including Omicron variants BA.4/BA.5 protein and N, M and S2 derived Th and CTL epitope peptides and an idealized pathogen derived artificial Th epitope peptide to offer effective prevention and treatment of long-haul COVID with specificities against SARS-CoV-2 VoCs including SARS-CoV-2 Omicron variants BA.4/BA.5. The disclosed vaccine compositions utilize amino acid sequences for the design and manufacture of optimal SARS-CoV-2 antigenic proteins, Th/CTL peptide immunogen constructs, CHO- derived S1- RBD VoCs-sFc proteins including CHO- derived S1-RBD Omicron variants BA.4/BA.5-sFc protein, and compositions thereof, as vaccines for prevention and treatment of long-haul COVID.

    SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
    6.
    发明申请
    SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY 审中-公开
    用于治疗过敏症的合成IgE膜锚定肽免疫球蛋白

    公开(公告)号：WO1996012740A1

    公开(公告)日：1996-05-02

    申请号：PCT/US1995013841

    申请日：1995-10-25

    Applicant: UNITED BIOMEDICAL, INC. ,  WANG, Chang, Yi ,  WALFIELD, Alan, M.

    Inventor： UNITED BIOMEDICAL, INC.

    IPC: C07K16/100

    CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/0008 ,  A61K2039/6018 ,  A61K2039/6031 ,  A61K2039/64 ,  C07K16/00 ,  C12N2730/10122 ,  C12N2760/18422

    Abstract: The present invention relates to a method for eliciting the production in healthy mammals, including humans, of high titer antibodies specific for sites on the extracellular segment of the anchor domain of the membrane-bound epsilon heavy chain of B cell-expressed humain IgE by the use of a composition comprising a synthetic peptide immunogen containing extracellular membrane anchor sites, to reduce IgE-secreting B leukocytes and allergen-induced IgE production. It also relates to the use of optimally designed, carrier protein free, IgE epsilon -chain related immunogens as key components in a synthetic vaccine to provide an immunotherapy for the treatment of allergy. The subject peptides contain immune stimulator sequences, including a tandemly linked helper T cell epitope, to aid in stimulating the immune response towards the mIgE membrane anchor domain.

    Abstract translation: 本发明涉及一种在健康哺乳动物（包括人）中产生高效价抗体的方法，所述高滴度抗体对B细胞表达的人IgE的膜结合的ε重链的锚结构域的细胞外区段上的位点具有特异性 使用包含含有细胞外膜锚定位点的合成肽免疫原的组合物，以减少分泌白细胞的白细胞和变应原诱导的IgE产生。 它还涉及使用最佳设计的载体蛋白质，IgEε链相关免疫原作为合成疫苗的关键组分，为治疗过敏提供免疫治疗。 主题肽含有免疫刺激剂序列，包括串联的辅助T细胞表位，以帮助刺激针对mIgE膜锚定结构域的免疫应答。

    SYNTHETIC PEPTIDE BASED IMMUNOGENS FOR THE TREATMENT OF ALLERGY
    7.
    发明申请
    SYNTHETIC PEPTIDE BASED IMMUNOGENS FOR THE TREATMENT OF ALLERGY 审中-公开
    用于治疗过敏症的基于合成肽的免疫原

    公开(公告)号：WO1995026365A1

    公开(公告)日：1995-10-05

    申请号：PCT/US1995003741

    申请日：1995-03-24

    Applicant: UNITED BIOMEDICAL, INC. ,  WANG, Chang, Yi

    Inventor： UNITED BIOMEDICAL, INC.

    IPC: C07K19/00

    CPC classification number: C07K16/00 ,  A61K39/0005 ,  A61K2039/645 ,  C07K16/4291 ,  C07K19/00

    Abstract: The present invention relates to a method for eliciting the production in healthy mammals, including humans, of high titer antibodies to an effector site in human IgE heavy chain, i.e. a site in the CH4 domain of the ELEMENT -chain, by the use of compositions of synthetic peptide immunogens in either a radially branching multimeric form (such as branching octameric or hexadecameric peptides) or a linearly arranged monomeric form, to inhibit mast cell activation and reduce allergen-induced IgE production. It also relates to the use of such "optimally" designer, carrier protein free, IgE ELEMENT -chain related immunogens as key components in a synthetic vaccine to provide an immunotherapy for the treatment of allergy. The subject peptides contain immune stimulator sequences, including a built-in helper T cell epitope tandemly linked in a specific orientation, to aid in stimulating the immune response towards the IgE CH4 domain.

    Abstract translation: 本发明涉及一种在健康哺乳动物（包括人）中产生人类IgE重链中效应位点的高滴度抗体的方法，即ELEMENT链的CH4结构域中的位点，通过使用组合物 的合成肽免疫原以径向分支的多聚体形式（例如支化八聚体或十六聚体肽）或线性排列的单体形式，以抑制肥大细胞活化并降低变应原诱导的IgE产生。 它还涉及使用这种“最佳”设计者，无载体蛋白质，IgE ELEMENT-链相关免疫原作为合成疫苗中的关键组分，以提供用于治疗过敏的免疫治疗。 主题肽含有免疫刺激剂序列，包括以特定方向串联连接的内在辅助T细胞表位，以帮助刺激针对IgE CH4结构域的免疫应答。

    SYNTHETIC PEPTIDE-BASED MARKER VACCINE AND DIAGNOSTIC SYSTEM FOR EFFECTIVE CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS)
    9.
    发明申请
    SYNTHETIC PEPTIDE-BASED MARKER VACCINE AND DIAGNOSTIC SYSTEM FOR EFFECTIVE CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) 审中-公开
    基于合成肽的标记疫苗和用于有效控制磷酸盐生殖和呼吸综合征（PRRS）的诊断系统

    公开(公告)号：WO2013101195A1

    公开(公告)日：2013-07-04

    申请号：PCT/US2011/068133

    申请日：2011-12-30

    Applicant: UNITED BIOMEDICAL, INC. ,  Wang, Chang Yi

    Inventor： Wang, Chang Yi

    IPC: A61K39/12 ,  A61P31/12

    CPC classification number: A61K39/12 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/6031 ,  A61K2039/627 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/10034 ,  G01N33/56983 ,  G01N2333/08

    Abstract: A peptide-based marker vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) and a set of immunodiagnostic tests for the prevention, monitoring and control of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from PRRSV GP2, GP3, GP4, or GP5 proteins; each peptide individually contains a B cell PRRSV neutralizing/receptor binding epitope which is individually linked to an artificial T helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the T helper epitopes derived from the PRRSV GP4, GP5, M and Nucleocapsid proteins to provide cell mediated immunity. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide cross protection of PRRSV antibody free pigs from infection upon PRRSV challenge.

    Abstract translation: 公开了一种针对猪生殖和呼吸综合征（PRRS）的基于肽的标记疫苗和一套用于预防，监测和控制猪繁殖与呼吸综合征病毒（PRRSV）的免疫诊断试验。 根据本发明各种实施方案的疫苗制剂含有衍生自PRRSV GP2，GP3，GP4或GP5蛋白的肽的混合物; 每个肽单独含有B细胞PRRSV中和/受体结合表位，其与人工T辅助表位单独连接以增强各自的免疫原性; 并且其可以补充表示衍生自PRRSV GP4，GP5，M和Nucleocapsid蛋白的T辅助表位的肽的混合物，以提供细胞介导的免疫。 这样的病毒肽组合物在可接受的递送系统中制备为疫苗制剂，并且可以在PRRSV攻击时提供免于PRRSV抗体的猪免受感染的交叉保护。

    IMMUNOGENIC LHRH PEPTIDE CONSTRUCTS AND SYNTHETIC UNIVERSAL IMMUNE STIMULATORS FOR VACCINES
    10.
    发明申请
    IMMUNOGENIC LHRH PEPTIDE CONSTRUCTS AND SYNTHETIC UNIVERSAL IMMUNE STIMULATORS FOR VACCINES 审中-公开
    免疫原性LHRH胶原蛋白和合成通用免疫刺激物

    公开(公告)号：WO1994025060A1

    公开(公告)日：1994-11-10

    申请号：PCT/US1994004832

    申请日：1994-04-28

    Applicant: LADD, Anna, E. ,  WANG, Chang, Yi ,  ZAMB, Timothy

    IPC: A61K37/38

    CPC classification number: C07K14/005 ,  A61K39/0006 ,  A61K2039/6031 ,  C07K7/23 ,  C07K14/235 ,  C07K14/24 ,  C07K14/245 ,  C07K14/295 ,  C07K14/33 ,  C07K14/34 ,  C07K14/445 ,  C07K14/575 ,  C07K14/57572 ,  C07K14/595 ,  C07K16/00 ,  C07K19/00 ,  C12N2730/10122 ,  C12N2740/16222 ,  C12N2760/18722 ,  Y02A50/412

    Abstract: This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, Chlamydia MOMP peptides, HIV V3 peptides and Plasmodium berghei.

    Abstract translation: 本发明涉及导致男性或女性LHRH活性抑制的免疫原性促黄体激素释放激素（LHRH）肽。 当用这些肽免疫雄性大鼠时，血清睾丸激素下降和雄激素依赖性器官萎缩。 这些肽可用于诱导不育症和用于治疗男性前列腺增生，雄激素依赖性癌，前列腺癌和睾丸癌。 在女性中，肽可用于治疗子宫内膜异位症，良性子宫肿瘤，复发性功能性卵巢囊肿和（严重）经前期综合征以及预防或治疗雌激素依赖性乳腺癌。 受试肽含有辅助T细胞表位，并在C末端具有LHRH。 辅助T细胞表位有助于刺激对LHRH的免疫应答。 肽可任选地含有作为一般免疫刺激剂的侵袭素结构域。 在另一方面，本发明涉及具有侵入蛋白结构域，辅助T细胞表位和肽半抗原的免疫原性合成肽以及使用这些肽治疗疾病或提供保护性免疫的方法。 本发明的肽半抗原包括LHRH，胰岛淀粉样多肽，胃泌素，胃泌素释放肽，IgE CH4肽，衣原体MOMP肽，HIV V3肽和疟原虫。

Patent Agency Ranking